Pharmafocus offers an overview of this year’s Veeva Summit EU, held in Zürich. We share insights from key figures in the industry, who enlightened us about the potential of digital clinical trials, and the importance of ensuring patient centricity.
5. Leaked data reveals NHS will miss target for 50,000 nurses by 2024
The government could miss its target by over 10,000 nurses, according to leaked NHS modelling, with figures showing that the number of unfilled nursing jobs is in fact rising.
9. New genetic eye disease discovered
Researchers have identified a new disease that affects the macula. This new type of macular dystrophy is a cause of central vision loss.
Georgios Tsatsaronis, Vice President Data Science Research Content at Elsevier, offers insight into what role data scientists play in developing new and innovative therapeutics.
Pharmafocus speaks to Paul Davis at GADx about the increasing importance of antigen tests in tackling future pandemics,

Our Team

Executive Director – PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial and Content Assistant
Lina Adams
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2022 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.